SCHEMBL2770089

SCHEMBL2770089

Cc1nc(N)cc(-c2c(Nc3cccc(N4CCN(C)CC4)c3)nc3cccnn23)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 11/20 0.58
MTOR P42345 11/20 0.58
JAK2 O60674 2/20 0.42
JAK3 P52333 2/20 0.42
PTK2 Q05397 1/20 0.42
FLT3 P36888 4/20 0.41
CDK2 P24941 4/20 0.41
PLK4 O00444 1/20 0.41
CHEK1 O14757 1/20 0.41
PRKD3 O94806 1/20 0.41
LCK P06239 1/20 0.41
CSF1R P07333 1/20 0.41
ROS1 P08922 1/20 0.41
KIT P10721 1/20 0.41
FGFR1 P11362 1/20 0.41
SRC P12931 1/20 0.41
FLT1 P17948 1/20 0.41
FGFR3 P22607 1/20 0.41
MARK3 P27448 1/20 0.41
KDR P35968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772205 0.91 PIK3CA (0.59) PIK3CAMTORCDK2KDRGSK3B
SCHEMBL11029646 0.87 PIK3CA (0.68) PIK3CAMTORSRCPIK3CDPIK3CB
SCHEMBL11029742 0.81 PIK3CA (0.70) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL754291 0.80 PIK3CA (0.55) PIK3CAMTORJAK2FLT3PIK3CD
SCHEMBL2770778 0.80 PIK3CA (0.67) PIK3CAMTORCDK2PIK3CDPIK3CB
SCHEMBL750572 0.79 PIK3CA (0.60) PIK3CAMTORFLT3KITPIK3CD
SCHEMBL2774275 0.79 PIK3CA (0.60) PIK3CAMTORJAK2JAK3PTK2
SCHEMBL752803 0.78 PIK3CA (0.58) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL754099 0.77 PIK3CA (0.66) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL755064 0.77 PIK3CA (0.58) PIK3CAMTORJAK3PIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885JAK2 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.